Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Change of Registered Office

14 Apr 2016 07:00

RNS Number : 1219V
Tissue Regenix Group PLC
14 April 2016
 

Tissue Regenix Group plc

Change of Registered Office

Leeds, 14th April 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that the Company's Registered Office address has changed from The Biocentre, Innovation Way, Heslington, York, YO10 5NY to: Unit 1 & 2, Astley Way, Astley Lane Industrial Estate, Swillington, Leeds LS26 8XT with immediate effect.

 

 

For more Information:

 

Tissue Regenix Group plc

Caitlin Pearson Corporate Communications Officer

 

Tel: 0330 430 3073

Jefferies International Ltd

Simon Hardy / Harry Nicholas

 

Tel: 020 7029 8000

 

Tulchan CommunicationsJames Macey-White / Matt Low

Tel: 020 7353 4200

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

 In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CROZMGMDKFGGVZM

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.